Hormonal
Pomegranate-derived phytochemicals, specifically anthocyanins (ATs) and urolithins (metabolites of hydrolyzable tannins), exhibit anti-cancer and cardioprotective bioactivities through mechanisms including aromatase inhibition, apoptosis induction, and oxidative stress reduction.
This paper reviews laboratory and animal studies showing that compounds in pomegranate (like anthocyanins and urolithins) can inhibit cancer cell growth and support heart health in controlled settings. However, it explicitly notes that these findings have not been confirmed in human clinical trials. Do not use pomegranate supplements as a treatment for cancer or heart disease without consulting a physician, as the clinical efficacy and dosage protocols for humans are not established.
Emerging experimental evidence has suggested that urolithins play a major role in the anti-cancer, anti-inflammatory, and anti-aging activities of pomegranate fruit and products... ATs can quench free radicals... inhibit the activity of xanthine oxidase... and chelate metal ions... urolithins... competitively inhibited and most effectively suppressed the aromatase activity... induced apoptosis in the LNCaP cells
Why this rating
Evidence is derived entirely from in vitro cell lines and animal models; no human clinical trials are reported.
Source
Diverse Phytochemicals and Bioactivities in the Ancient Fruit and Modern Functional Food Pomegranate (Punica granatum)
Sheng Wu et al. · Molecules · 2017
DOI 10.3390/molecules22101606
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →